azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead developmen

First Wave BioPharma, Inc. Common Stock

Bought 4% more FWBI

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Antonio Montana

Bought 29% more FWBI

Bought 2% more FWBI

Bought 15% more FWBI

Bought 13% more FWBI

Bought 43% more FWBI

Sold all FWBI

Mike Pelech

New position in FWBI

Bought 5% more FWBI

Bought 6% more FWBI

Bought 23% more FWBI

Bought 30% more FWBI

Bought 11% more FWBI

Bought 12% more FWBI